Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 9/20 | 0.43 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.41 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.41 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828396 | 0.91 | PIK3CD (0.48) | NSD2PIK3CDPIK3R1PIK3CGPI4KA | |
| SCHEMBL30013691 | 0.89 | PIK3CD (0.46) | NSD2NSD3PIK3CDPIK3R1PIK3CG | |
| SCHEMBL8426 | 0.89 | PIK3CD (0.46) | NSD2NSD3PIK3CDPIK3R1PIK3CG | |
| SCHEMBL30013561 | 0.89 | NSD2 (0.44) | NSD2NSD3PIK3CDPIK3R1PIK3CG | |
| SCHEMBL8080 | 0.89 | NSD2 (0.44) | NSD2NSD3PIK3CDPIK3R1PIK3CG | |
| SCHEMBL8903 | 0.82 | ADORA2A (0.49) | NSD2NSD3PIK3CDPIK3R1PIK3CG | |
| SCHEMBL30013159 | 0.82 | ADORA2A (0.49) | NSD2NSD3PIK3CDPIK3R1PIK3CG | |
| SCHEMBL13725952 | 0.82 | ADORA2A (0.44) | NSD2NSD3PIK3CDPIK3R1PIK3CG | |
| SCHEMBL8575 | 0.80 | ADORA2A (0.46) | NSD2NSD3PIK3CDPIK3R1PIK3CG | |
| SCHEMBL8770 | 0.80 | NSD2 (0.47) | NSD2NSD3PIK3CDPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | claimed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | claimed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | claimed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | claimed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | claimed |
| EP-2705029-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | Rhizen Pharmaceuticals S.A. (CH) | 2014-03-12 | — | — | EP | claimed |
| WO-2012151525-A9 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | claimed |
| WO-2012151525-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-08 | — | — | WO | claimed |
| EP-2916868-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS S A (CH) | 2022-05-11 | — | — | EP | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | RHIZEN PHARMACEUTICALS SA (CH) | 2021-07-20 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| EP-2916868-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | Rhizen Pharmaceuticals S.A. (CH) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014072937-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS SA (CH) | 2014-05-15 | — | — | WO | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | NSD2 3897/4885NSD3 3066/4885PIK3CD 47/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | NSD2 3370/4885NSD3 3117/4885PIK3CD 288/4885 |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | NSD2 3897/4885NSD3 3066/4885PIK3CD 47/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | NSD2 3897/4885NSD3 3066/4885PIK3CD 47/4885 |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKAR2B | NSD2 4249/4885NSD3 3091/4885PIK3CD 89/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | NSD2 3897/4885NSD3 3066/4885PIK3CD 47/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | NSD2 4204/4885NSD3 3987/4885PIK3CD 148/4885 |
| US-11065236-B2 | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor | PIK3CD, PIK3R4, PIK3CG | NSD2 3751/4885NSD3 3755/4885PIK3CD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.